Sumitomo Pharma Co Ltd
TSE:4506
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
285
684
|
| Price Target |
|
We'll email you a reminder when the closing price reaches JPY.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Sumitomo Pharma Co Ltd
Sumitomo Pharma Co Ltd
Selling, General & Administrative
Sumitomo Pharma Co Ltd
Selling, General & Administrative Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Selling, General & Administrative | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Sumitomo Pharma Co Ltd
TSE:4506
|
Selling, General & Administrative
-¥383.6B
|
CAGR 3-Years
-20%
|
CAGR 5-Years
-24%
|
CAGR 10-Years
-8%
|
|
|
Takeda Pharmaceutical Co Ltd
TSE:4502
|
Selling, General & Administrative
-¥1.1T
|
CAGR 3-Years
-7%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
-7%
|
|
|
Daiichi Sankyo Co Ltd
TSE:4568
|
Selling, General & Administrative
-¥696.7B
|
CAGR 3-Years
-26%
|
CAGR 5-Years
-20%
|
CAGR 10-Years
-5%
|
|
|
Otsuka Holdings Co Ltd
TSE:4578
|
Selling, General & Administrative
-¥925.7B
|
CAGR 3-Years
-16%
|
CAGR 5-Years
-10%
|
CAGR 10-Years
-4%
|
|
|
Chugai Pharmaceutical Co Ltd
TSE:4519
|
Selling, General & Administrative
-¥108.4B
|
CAGR 3-Years
-3%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
-3%
|
|
|
Astellas Pharma Inc
TSE:4503
|
Selling, General & Administrative
-¥795.7B
|
CAGR 3-Years
-14%
|
CAGR 5-Years
-10%
|
CAGR 10-Years
-7%
|
|
Sumitomo Pharma Co Ltd
Glance View
In the bustling world of pharmaceuticals, Sumitomo Pharma Co. Ltd. stands as a testament to innovation and resilience. Emerging from its roots in Sumitomo Dainippon Pharma, this Japanese giant has been weaving a complex tapestry of cutting-edge medical advancements and strategic mergers for decades. At its core, Sumitomo Pharma is fueled by an unwavering commitment to research and development, driving its efforts in therapeutic areas such as psychiatry, neurology, and oncology. These focal points aren't mere business segments but vital lifelines that the company seeks to improve with its products. Their success heavily relies on their ability to translate research into actionable, marketable treatments; it's a dance between science and commerce, with the rhythm dictated by patient needs and market demands. Sumitomo Pharma's financial engine is powered not just by their innovative drug pipeline but also through savvy global partnerships and strategic acquisitions. By expanding its footprint across North America, Europe, and Asia, the company meticulously builds a global distribution network that ensures its products reach the hands of physicians and patients worldwide. This extensive reach allows Sumitomo Pharma to tap into diverse markets, fueling both sales and brand recognition. Moreover, through its alliances with biotech firms and academic institutions, the company enhances its research capabilities, fostering a cycle of innovation that feeds back into its financial growth. In essence, Sumitomo Pharma doesn't just participate in the pharmaceutical industry; it actively shapes it, both through its dedication to breakthrough therapies and its strategic navigation of complex global markets.
See Also
What is Sumitomo Pharma Co Ltd's Selling, General & Administrative?
Selling, General & Administrative
-383.6B
JPY
Based on the financial report for Sep 30, 2024, Sumitomo Pharma Co Ltd's Selling, General & Administrative amounts to -383.6B JPY.
What is Sumitomo Pharma Co Ltd's Selling, General & Administrative growth rate?
Selling, General & Administrative CAGR 10Y
-8%
Over the last year, the Selling, General & Administrative growth was -28%. The average annual Selling, General & Administrative growth rates for Sumitomo Pharma Co Ltd have been -20% over the past three years , -24% over the past five years , and -8% over the past ten years .
You don't have any saved screeners yet
